Jul 2026· International Journal of Current Science Research and Review· Vol 09· 0 citations
TL;DR
The recent developments, therapeutic applications, challenges, and future perspectives of Nanoparticle based cancer drug delivery systems are summarized.
Abstract
Cancer is one of the major causes of Mortality around the world, Despite Having significant advances in diagnosis and treatment. Conventional therapeutic-based approaches such as chemotherapy, radiotherapy, and surgeries are often limited due to poor selectivity, Toxicity, inadequate accumulation of drugs at tumor sites, and development of resistance to multi-drugs. Nanotechnology has developed as a better platform for improving Cancer treatment through the development of Nanoparticle based System of drug delivery. These nanoparticles have unique Physical and chemical properties that include It’s nano scale size, Large surface area and its characteristics, enhanced drug-loaded capacity and controlled release of the drugs. These kind of properties helps to fight cancer cells by minimising damage to the healthy tissues. Various kinds of nanoparticles, Such as dendrimers, metallic nanoparticles, liposomes, and hybrid nano carriers, result in better therapeutic Outcomes in preclinical and clinical studies. Recent advancements Which include Smart Nanoparticles, gene delivery systems, Immunotherapy based Nanomedicines and environment responsive drug delivery systems for tumors, Etc. These nanoparticle-based therapies have a better potential for multi-drug resistance and enhance the treatment efficiency. Despite having these advancements, there are also some challenges Which includes toxicity, Biological effects, Manufacturing And regulatory approval. This affects its widespread use for clinical treatments. This review therefore summarizes the recent developments, therapeutic applications, challenges, and future perspectives of Nanoparticle based cancer drug delivery systems.
Cancer remains one of the leading causes of morbidity and mortality worldwide despite substantial advances in diagnosis and treatment. Conventional therapeutic approaches, including chemotherapy, radiotherapy, surgery, and immunotherapy, are often limited by poor tumor selectivity, systemic toxicity, multidrug resistance, and inadequate drug accumulation at the disease site. Nanomedicine has emerged as a transformative strategy in oncology, offering innovative solutions for targeted drug delivery, improved pharmacokinetics, enhanced therapeutic efficacy, and reduced off-target toxicity. Owing to their unique physicochemical properties, nanoparticles can be engineered to overcome biological barriers associated with tumor progression and facilitate precise delivery of therapeutic and diagnostic agents. This review comprehensively discusses the fundamental principles of cancer nanomedicine, including tumor biology, barriers to drug delivery, and critical design considerations for nanocarrier development. Various classes of nanomaterials, including polymeric nanoparticles, lipid-based systems, inorganic nanomaterials, and emerging biomimetic platforms, are examined with respect to their structural characteristics, therapeutic applications, and translational potential. Particular emphasis is placed on tumor-targeting strategies, encompassing passive, active, and microenvironment-responsive approaches, as well as on the development of smart stimuli-responsive nanocarriers capable of controlled, site-specific drug release. Furthermore, recent advances in nanotechnology-enabled chemotherapy, combination therapy, gene and RNA delivery, immuno-nanomedicine, and theranostic platforms are highlighted. The integration of diagnostic imaging and therapeutic functions within multifunctional nanocarriers has enabled real-time monitoring of treatment response and personalized cancer management. In addition, challenges associated with safety, toxicity, large-scale manufacturing, regulatory approval, and clinical translation are critically evaluated. Emerging innovations, including artificial intelligence-driven nanocarrier design, biomimetic nanomedicines, and precision oncology approaches, are also explored as future directions for the field.Overall, cancer nanomedicine has evolved from a simple drug-delivery concept into a multifunctional therapeutic platform integrating targeted therapy, molecular imaging, immunomodulation, gene therapy, and personalized medicine. Continued interdisciplinary collaboration and technological innovation are expected to accelerate the clinical translation of next-generation nanomedicines, ultimately improving treatment outcomes and advancing precision cancer care.
Fouzan Arif Mulla Mulla, Mo Saad Sanaullah Khan Khan, Irfan Nizamuddin Mansuri Mansuri et al.· Journal of Pharmacology, Gen...· 0 citations
An up-to-date summary of the use of nanomaterials in lung cancer therapy is provided by categorising various types of nanocarriers, discussing their mechanisms for circumventing physiological barriers and emphasizing their role in the development of next-generation therapies, especially immunotherapy and molecular diagnostics (theranostics).
Ramaraj Rajesh Kumar, I. V. Enoch· Lung Cancer· 0 citations
Cancer is one of the leading causes of death around the globe. The conventional cancer
therapies have several drawbacks, like non-specific biodistribution, poor stability, and significant
systemic toxicity. Nanogels are increasingly recognized as a promising type of nanocarrier for cancer
therapy because of their structural versatility, biocompatibility, and remarkable drug-loading
efficiency. As cross-linked polymeric hydrogel nanoparticles, they offer multiple benefits, including
enhancing the solubility of hydrophobic drugs, enabling controlled and stimulus-responsive release,
improving tumour-specific delivery through the enhanced permeability and retention (EPR) effect,
and reducing systemic toxicity. Recent progress in nanogel engineering has introduced smart
modifications such as pH-, temperature-, enzyme-, and redox-responsive designs, which allow exact
and localized drug release within the tumor microenvironment. The present review provides a
comprehensive overview of nanogels, their types, and effects on various types of cancers.
Bhaskar Jyoti Deka, Samina Sultana, M. A. Laskar et al.· Current Cancer Therapy Revie...· 0 citations
Nanotechnology has become a revolutionary technology in contemporary medicine that can provide new solutions to the inefficiency of the traditional drug delivery systems. Nanoscale properties enable precise drug targeting, controlled release, enhanced bioavailability, and reduced systemic toxicity. The review gives a general description of drug delivery systems that are based on nanotechnology, with liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, and metallic nanoparticles being the main examples of nanocarriers. Critical discussions are made of their design strategies, drug loading capacities, release mechanisms and therapeutic advantages. In addition, more recent technological developments in the areas of targeted delivery, such as ligand-mediated delivery and stimuli-responsive systems, are discussed in the treatment of various diseases in cancer, infections, and neurological conditions. Despite significant advancements, there are still issues of toxicity, stability, large-scale production, and regulatory issues, which are impediments to clinical translation. In general, the field of nanotechnology offers a potential platform in improving therapeutic efficacy and development of biomaterial-based medical applications.
Shalini Tiwari, S. Kotnala, Rohinee Bhandari et al.· Trends in Biomaterials & Art...· 0 citations
This comprehensive review provides details on nanocarriers and their loaded delivery systems as effective strategies for breast cancer treatment and provides an updated synthesis of nanocarrier-based approaches, focusing on recent clinical and preclinical innovations in drug delivery, diagnostics, and personalized medicine.
Prerana Sahu, G. Sahu, Harish Sharma et al.· Current Cancer Therapy Revie...· 0 citations
Breast cancer, one of the leading cancer types, directly contributes to cancer‐related mortality, but new therapies are required to improve treatment efficiency. Nanoparticle‐based strategies have already introduced the most radical advances in this regard, from their first formulation through their development to the next generation as promising candidates. The present review provides an overview of nanoparticle‐based strategies in breast cancer, their development, and their state of the art. The review addresses the diverse formulation of nanoparticles, including liposomes, dendrimers, and metallic nanoparticles, as well as their respective roles in drug delivery: bioavailability, focused therapeutic intervention, and lower systemic toxicity. This review covers studies on the engineering of nanoparticles for improved drug delivery, including cancer‐targeted delivery to tumors and optimization within the tumor microenvironment. Additionally, new nanosized drugs may also be utilized for novel modification of nanoparticle composition for combination therapeutics, which allows pharmacological agents to enter the tumor microenvironment by combined treatment with diverse types of other agents, to provide a synergistic, effective treatment in real time, in addition to real‐time monitoring. Stimuli‐responsive nanoparticles, which release the drug according to the appropriate stimulus signal to provide greater accuracy and regulation in delivering the drug, are also under investigation. This review notes trends in personalized nanomedicine and nanoparticle‐mediated immunotherapy that target personalized patient and immune responses, among others. Other exciting areas for nanoparticle research include AI‐based optimal design and sustainable biodegradable materials aimed at maintaining nanoparticle safety. Nanoparticle‐based therapies are a unique new frontier in breast cancer therapy. They have considerable clinical potential, offer promise for patient‐specific treatment, and warrant further investigation in breast cancer, particularly in advanced targeting mechanisms, multifunctional approaches, and individualized interventions.
Sina M Matalqah, Laila M Matalqah, A. R. Al Tawaha et al.· International Journal of Bre...· 2 citations